Here's why the BPH Energy (ASX:BPH) share price is surging 5% today

BPH shares look set to finish the week higher.

| More on:
An anaesthetist in an operating theatre looks at a computer screen while patient sleeps

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The BPH Energy Ltd (ASX: BPH) share price is roaring higher during afternoon trade on Friday.

This comes as the biotechnology and mineral exploration company announced an update in regards to its investee company, Cortical Dynamics.

At the time of writing, BPH shares are up 5.08% to 6.2 cents. It's worth noting that its shares reached an intraday high of 6.7 cents before treading lower.

What did BPH announce?

Investors are pushing the BPH share price upwards after digesting the company's latest positive update.

According to its release, BPH advised that Cortical Dynamics has filed a 510(k) submission with the United States Food and Drug Administration (FDA). This is in relation to the company's medical device, the Brain Anaesthesia Response Monitor (BARM).

Touted as the next-generation brain function monitor, BARM is an Australian-first. It has been developed by BPH in partnership with Swinburne University.

BARM works by measuring changes in a patient's brain activity as a medical professional delivers anaesthesia. It allows anaesthetists to calculate the dosage and make adjustments as necessary during surgical procedures.

The monitor also has the potential to indicate how pain-free a patient is while under anaesthesia.

BARM is better than the currently used electroencephalogram (EEG) technology because it is based on science's latest understanding of how the brain produces rhythmic electrical activity.

A 510(k) is a premarket submission that demonstrates that the device is safe and effective for potential consumers. This is considered the fastest route to market. Clearance of the 510(k) would allow Cortical Dynamics to begin marketing a predicate device in the US without clinical trials.

About the BPH share price

Over the past 12 months, BPH shares have lifted by 24%. Year to date, the BPH share price has gained 55%.

Based on today's price, BPH presides a market capitalisation of roughly $41.2 million. There are approximately 665 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »